MKI67 and inflammatory breast carcinoma: Furthermore, immunostaining revealed that most of the patients with invasive breast carcinoma (IBC) strongly expressed Ki-67 (Ki-67+) and BCL-2 (BCL-2+), with proportions of 85.5% (65/76) and 57.9% (44/76) respectively.